Micrima Raises Additional £4.4 million for State-of-the-art Breast Cancer Screening Technology

June 19, 2018

UK-based breast imaging company, Micrima has raised £4.4 million in additional equity funding led by Technology Venture Partners, The Angel CoFund(ACF), and Venture Founders – plus a group of returning and new individual investors – bringing the total amount raised to £10.7m.

Micrima’s patented MARIA breast cancer screening system is currently for use in symptomatic clinics, and it is intended that it will eventually be widely adopted as a viable alternative to mammography breast screening. It is unique in that it uses harmless radio-waves to detect breast cancer – unlike mammography that uses ionising radiation – requires no breast compression, so is painless for women, but is also a whole-breast method of imaging compared to some modalities that use a handheld probe. In clinical trials it has proven to be particularly effective in dense tissue[1], where the current screening technology struggles. It has been trialled in over 400 women in the United Kingdom, with further trials just about to commence at leading European centres.

See the full article on the Journal of mHealth website here